Literature DB >> 20600074

Scintillation proximity assay for total p53 protein as an alternative to ELISA.

Sarit Oberlander1, Tian Xie, Uma Chandrachud, Susannah Gal.   

Abstract

Measurement of the level of a specific protein can be an important parameter to discern as that can change and reflect disease status. A number of methods have been developed to quantitate the level of a protein, some amenable to high throughput screening. A method is described to measure the total level of the tumor suppressor p53 using scintillation proximity assay (SPA) beads and radiolabeled streptavidin. Three different cell extracts were used, with one used to develop the standard curve for the amount of p53. This method allows the specific detection of p53 in the range of 50 to 300 pg in 10 microl of an extract. While this detection is less than what can be detected by commercially available enzyme linked immunosorbent assay (ELISA) kits, the SPA compares favorably on time required and cost. This new assay also has the potential to be coupled with measurements for p53 DNA binding, a unique aspect of this approach. 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20600074      PMCID: PMC2924953          DOI: 10.1016/j.jim.2010.06.018

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  10 in total

1.  Scintillation proximity assay for DNA binding by human p53.

Authors:  Susannah Gal; Jeffery R Cook; Leighton Howells
Journal:  Biotechniques       Date:  2006-09       Impact factor: 1.993

Review 2.  Scintillation proximity assays in high-throughput screening.

Authors:  J Fraser Glickman; Andres Schmid; Sandrine Ferrand
Journal:  Assay Drug Dev Technol       Date:  2008-06       Impact factor: 1.738

3.  Chimeric IgG-binding receptors engineered from staphylococcal protein A and streptococcal protein G.

Authors:  M Eliasson; A Olsson; E Palmcrantz; K Wiberg; M Inganäs; B Guss; M Lindberg; M Uhlén
Journal:  J Biol Chem       Date:  1988-03-25       Impact factor: 5.157

Review 4.  Assessing p53 in clinical contexts: unlearned lessons and new perspectives.

Authors:  Peter A Hall; W Glenn McCluggage
Journal:  J Pathol       Date:  2006-01       Impact factor: 7.996

5.  New ELISA technique for analysis of p53 protein/DNA binding properties.

Authors:  Eva Jagelská; Václav Brázda; Sarka Pospisilová; Borivoj Vojtesek; Emil Palecek
Journal:  J Immunol Methods       Date:  2002-09-15       Impact factor: 2.303

Review 6.  Mdm2-mediated ubiquitylation: p53 and beyond.

Authors:  J-C Marine; G Lozano
Journal:  Cell Death Differ       Date:  2010-01       Impact factor: 15.828

7.  Development of a scintillation proximity assay for human insulin-like growth factor-binding protein 4 compatible with inhibitor high-throughput screening.

Authors:  X Z Khawaja
Journal:  Anal Biochem       Date:  2007-03-18       Impact factor: 3.365

8.  Three assays show differences in binding of wild-type and mutant p53 to unique gene sequences.

Authors:  Uma Chandrachud; Susannah Gal
Journal:  Technol Cancer Res Treat       Date:  2009-12

Review 9.  Modes of p53 regulation.

Authors:  Jan-Philipp Kruse; Wei Gu
Journal:  Cell       Date:  2009-05-15       Impact factor: 41.582

10.  High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas.

Authors:  J A Fagin; K Matsuo; A Karmakar; D L Chen; S H Tang; H P Koeffler
Journal:  J Clin Invest       Date:  1993-01       Impact factor: 14.808

  10 in total
  1 in total

1.  Diagnostic and prognostic markers in differentiated thyroid cancer.

Authors:  José M Gómez Sáez
Journal:  Curr Genomics       Date:  2011-12       Impact factor: 2.236

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.